文献速递肝病

严重慢加急性肝衰竭患者因基于终末期肝病模型的分配合策而处于不利地位

Patients with severe acute-on-chronic liver failure are disadvantaged by model for end-stage liver disease-based organ allocation policy.
PubMed 文献 · Aliment Pharmacol Ther · 2020-07-29

该研究分析2010-2017年UNOS数据库中6342例MELD-Na评分≥35的候选者,其中3122例为ACLF-3。竞争风险回归显示ACLF-3患者90天等待名单死亡风险显著高于较低ACLF级别者(SHR=1.41;95%CI 1.12-1.78),且4-6个器官衰竭者肝移植可能性最低(SHR=0.61;95%CI 0.54-0.68)。结论认为MELD-Na评分使ACLF-3患者处于不利地位,将器官衰竭纳入分配合策值得进一步探索。

要点

  • MELD-Na评分≥35且ACLF-3患者90天等待名单死亡风险显著高于较低ACLF级别者。
  • ACLF-3伴4-6个器官衰竭者等待名单死亡风险最高且肝移植可能性最低。
  • Share 35规则仅与全体ACLF-3患者等待名单死亡率降低相关,对4-6个器官衰竭者无显著关联。

核心结论

  • MELD-Na评分使ACLF-3患者(无论是否伴肝外器官衰竭)处于不利地位。
  • 将器官衰竭纳入分配合策值得进一步探索。

研究设计与样本

  • 分析2010-2017年UNOS数据库的队列研究。
  • 纳入6342例列名时MELD-Na评分≥35的候选者,其中3122例为ACLF-3。
  • 使用Fine和Gray竞争风险回归评估等待名单结局。

主要发现

  • 列名时ACLF-3患者90天等待名单死亡风险显著高于较低ACLF级别者(SHR=1.41;95%CI 1.12-1.78)。
  • ACLF-3亚组中,3个器官衰竭者等待名单死亡风险增加(SHR=1.40;95%CI 1.20-1.63)。
  • ACLF-3亚组中,4-6个器官衰竭者等待名单死亡风险增加(SHR=3.01;95%CI 2.54-3.58)。
  • 4-6个器官衰竭者接受肝移植的可能性最低(SHR=0.61;95%CI 0.54-0.68)。
  • Share 35规则与全体ACLF-3且MELD-Na≥35患者90天等待名单死亡率降低相关(SHR=0.59;95%CI 0.49-0.70)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mortality for patients with acute-on-chronic liver failure (ACLF) may be underestimated by the model for end-stage liver disease-sodium (MELD-Na) score. AIM: To assess waitlist outcomes across varying grades of ACLF among a cohort of patients listed with a MELD-Na score ≥35, and therefore having similar priority for liver transplantation. METHODS: We analysed the United Network for Organ Sharing (UNOS) database, years 2010-2017. Waitlist outcomes were evaluated using Fine and Gray's competing risks regression. RESULTS: We identified 6342 candidates at listing with a MELD-Na score ≥35, of whom 3122 had ACLF-3. Extra-hepatic organ failures were present primarily in patients with four to six organ failures. Competing risks regression revealed that candidates listed with ACLF-3 had a significantly higher risk for 90-day waitlist mortality (Sub-hazard ratio (SHR) = 1.41; 95% confidence interval [CI] 1.12-1.78) relative to patients with lower ACLF grades. Subgroup analysis of ACLF-3 revealed that both the presence of three organ failures (SHR = 1.40, 95% CI 1.20-1.63) or four to six organ failures at listing (SHR = 3.01; 95% CI 2.54-3.58) was associated with increased waitlist mortality. Candidates with four to six organ failures also had the lowest likelihood of receiving liver transplantation (SHR = 0.61, 95% CI 0.54-0.68). The Share 35 rule was associated with reduced 90-day waitlist mortality among the full cohort of patients listed with ACLF-3 and MELD-Na score ≥35 (SHR = 0.59; 95% CI 0.49-0.70). However, Share 35 rule implementation was not associated with reduced waitlist mortality among patients with four to six organ failures (SHR = 0.76; 95% CI 0.58-1.02). CONCLUSIONS: The MELD-Na score disadvantages patients with ACLF-3, both with and without extra-hepatic organ failures. Incorporation of organ failures into allocation policy warrants further exploration.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Sundaram V, Shah P, Mahmud N, et al. Patients with severe acute-on-chronic liver failure are disadvantaged by model for end-stage liver disease-based organ allocation policy. Aliment Pharmacol Ther. 2020. PMID: 32725664. doi:10.1111/apt.15988

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。